Morgan Stanley keeps BridgeBio Oncology at "overweight" and cuts price target to $12 from $13
Morgan Stanley kept its "overweight" rating on BridgeBio Oncology and cut its price target to $12 from $13, a 7.7% reduction. The new target implies 518.6% upside versus the November 17 close of $1.94. The four most recent analyst notes on the company over the past 30 days set price targets between $9 and $16.
In 25 seconds
- Morgan Stanley keeps its "overweight" rating on BridgeBio Oncology.
- The price target drops to $12 from $13, a 7.7% cut.
- The new target implies 518.6% upside versus the November 17 close of $1.94.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.